These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8165617)

  • 41. Certain high molecular weight heparin chains have high affinity for vitronectin.
    Edens RE; LeBrun LA; Linhardt RJ; Kaul PR; Weiler JM
    Arch Biochem Biophys; 2001 Jul; 391(2):278-85. PubMed ID: 11437360
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Complex compounds of heparin with blood proteins and their natural inhibitors in splenectomy in animals].
    Liapina LA; Kondashevskaia MV; Azieva LD; Soboleva GI
    Patol Fiziol Eksp Ter; 1990; (4):20-2. PubMed ID: 2080078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interaction of a new depolymerized holothurian glycosaminoglycan with proteins in human plasma.
    Minamiguchi K; Nagase H; Kitazato KT; Kitazato K
    Thromb Res; 1996 Aug; 83(3):253-64. PubMed ID: 8840467
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complex formation of platelet thrombospondin with histidine-rich glycoprotein.
    Leung LL; Nachman RL; Harpel PC
    J Clin Invest; 1984 Jan; 73(1):5-12. PubMed ID: 6690483
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma free fatty acid levels influence Zn(2+) -dependent histidine-rich glycoprotein-heparin interactions via an allosteric switch on serum albumin.
    Kassaar O; Schwarz-Linek U; Blindauer CA; Stewart AJ
    J Thromb Haemost; 2015 Jan; 13(1):101-10. PubMed ID: 25353308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4.
    Lane DA; Pejler G; Flynn AM; Thompson EA; Lindahl U
    J Biol Chem; 1986 Mar; 261(9):3980-6. PubMed ID: 3949798
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A fluorescent probe assay (Heparin Red) for direct detection of heparins in human plasma.
    Warttinger U; Giese C; Harenberg J; Holmer E; Krämer R
    Anal Bioanal Chem; 2016 Nov; 408(28):8241-8251. PubMed ID: 27655335
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance.
    Manson L; Weitz JI; Podor TJ; Hirsh J; Young E
    J Lab Clin Med; 1997 Dec; 130(6):649-55. PubMed ID: 9422339
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A simple method for estimating a 'heparin binding capacity' of human serum.
    Pearson RD; Lubin AH
    Health Lab Sci; 1978 Jan; 15(1):32-7. PubMed ID: 640837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Mechanism of heparin binding by polycations in the presence of serum proteins].
    Mustafaev MI; Kabanov VA
    Farmakol Toksikol; 1980; 43(4):395-9. PubMed ID: 7439374
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antigenic structure of four human plasma proteins, retinol-binding protein, 9,5S-alpha-1-glycoprotein, alpha-2-pregnancy-associated glycoprotein and histidine-rich alpha-2-glycoprotein.
    Bauer K
    Exp Clin Immunogenet; 1986; 3(4):230-3. PubMed ID: 2484013
    [No Abstract]   [Full Text] [Related]  

  • 52. Simultaneous isolation and partial characterization of antithrombin III and alpha 1-proteinase inhibitor from horse plasma.
    Kurdowska A; Koj A; Jaśkowska M
    Acta Biochim Pol; 1982; 29(1-2):95-103. PubMed ID: 6983800
    [No Abstract]   [Full Text] [Related]  

  • 53. [Inhibitory and immunological profile of therapeutic serum protein solutions].
    Kotitschke R; Stephan W
    Infusionsther Klin Ernahr; 1985 Feb; 12(1):48-53. PubMed ID: 3886542
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Comparative pharmacokinetic study, in the dog, of low molecular weight heparin and standard heparin by labelling with 35S].
    Uzan A; Marin J; Mardiguian J; Trillou M; Kiosseff T; Rougeot C
    Ann Pharm Fr; 1987; 45(6):429-37. PubMed ID: 2847624
    [No Abstract]   [Full Text] [Related]  

  • 55. Heparin-binding properties of human serum spreading factor.
    Barnes DW; Reing JE; Amos B
    J Biol Chem; 1985 Aug; 260(16):9117-22. PubMed ID: 2410408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human plasma protein N-glycosylation.
    Clerc F; Reiding KR; Jansen BC; Kammeijer GS; Bondt A; Wuhrer M
    Glycoconj J; 2016 Jun; 33(3):309-43. PubMed ID: 26555091
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Membrane plasma filtration (MPF): effect of temperature on heparin and macromolecule sieving.
    Horiuchi T; Emura M; Usami M; Malchesky PS; Nose Y
    Trans Am Soc Artif Intern Organs; 1985; 31():692-7. PubMed ID: 3837534
    [No Abstract]   [Full Text] [Related]  

  • 58. [Binding of technetium 99m-labeled heparin and its low molecular weight fractions CY 216 and CY 222 to human endothelium in vitro].
    Psuja P
    Pol Tyg Lek; 1987 Jul; 42(30):903-6. PubMed ID: 2823236
    [No Abstract]   [Full Text] [Related]  

  • 59. [Heparin complex formation with plasma proteins in an analytic ultracentrifuge].
    Liapina LA; Zhitnikova ES; Boneva ZhS
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1982; (3):25-8. PubMed ID: 7074180
    [No Abstract]   [Full Text] [Related]  

  • 60. [Composition and properties of heparin and protamine complexes formed in the plasma].
    Roszkowska-Jakimiec W
    Acta Haematol Pol; 1985; 16(1-2):65-71. PubMed ID: 3832743
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.